Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston Apr 23, 2021 12:26pm
163 Views
Post# 33055494

RE:RE:I'm still trying to figure out

RE:RE:I'm still trying to figure out
Stoxxhp wrote: I'm not entirely sure how someone can be so incredibly and naively uneducated.
For all you or we know they are speaking with pfizer and they were told they need to amalgamate in order to proceed with partnership.
Is it really that impossible to read between the lines to figure that out as a possibility? 
 
Do you actually believe Dan is sitting there by himself making decisions? There are a whole host of people directing the decisions.

The ignorance and just complete lack of thought on this board is staggering.



Amalgamation would likely be necessary if Pfizer or another pharma is seeking more than a standard licensing deal.
 
Dan recently confirmed by email what he said during BioPub, that is, Antibe (and not Holdings) owns the IP associated with the new molecules activity.
 
This might explain in part why there is a need to unify the control/ownership of the IP at this time when previously the existing IH/ATE licensing arrangements sufficed. 
 
It looks like both Antibe and Holdings has somthing to offer at the negotiating table.  We will soon find out how much value is given to the new IP.
 

<< Previous
Bullboard Posts
Next >>